Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

1.58USD
9 Dec 2016
Change (% chg)

$0.02 (+1.28%)
Prev Close
$1.56
Open
$1.56
Day's High
$1.60
Day's Low
$1.56
Volume
22,581
Avg. Vol
48,702
52-wk High
$2.27
52-wk Low
$0.90

MEIP.OQ

Chart for MEIP.OQ

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $58.10
Shares Outstanding(Mil.): 36.77
Dividend: --
Yield (%): --

Financials

  MEIP.OQ Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -0.59 -- --
ROI: -41.12 -0.36 15.24
ROE: -41.75 -0.94 16.58

BRIEF-KBR Subsidiary Brown & Root Industrial Services LLC acquires MEI Group LLC

* Brown & Root Industrial Services, LLC has acquired MEI Group, LLC

Nov 15 2016

BRIEF-MEI Pharma Q1 loss $0.12/shr

* MEI Pharma - Believes cash, cash equivalents, short-term investments as of Sept. 30 to be sufficient to fund operations through at least calendar year 2017 Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-MEI pharma reports fiscal year 2016 results

* MEI Pharma reports fiscal year 2016 results Source text for Eikon: Further company coverage:

Sep 06 2016

BRIEF-MEI Pharma says board reduces size to 7 directors

* MEI Pharma says board has decided to reduce its size to seven directors - SEC filing

Sep 02 2016

BRIEF-Helsinn Investment Fund reports 7.1 pct passive stake in MEI Pharma - SEC filing

* Helsinn Investment Fund SA reports 7.1 pct passive stake in MEI Pharma Inc as of Aug. 16 - SEC filing Source text (http://bit.ly/2bxhh2P) Further company coverage:

Aug 22 2016

BRIEF-Helsinn Group, MEI Pharma enter deal for Pracinostat development

* Helsinn Group and Mei Pharma enter strategic agreement for the development and commercialization of pracinostat for the treatment of acute myeloid leukemia and other hematologic diseases

Aug 08 2016

BRIEF-MEI pharma's pracinostat receives FDA's breakthrough therapy designation

* MEI Pharma's pracinostat receives breakthrough therapy designation from FDA for treatment in combination with azacitidine of patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy

Aug 01 2016

Earnings vs. Estimates